Hepatocellular carcinoma
Conditions
Interventions
Miriplatin emulsion warmed at 60 degrees Celsius (maximum dose is 120mg) is injected through the catheter selectively introduced into the hepatic artery. Injection continues till tumor feeding arterie
Sponsors
Watadani Takeyuki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Hepatocellular carcinoma not appropriate for surgery or local ablation therapy (e.g. radiofrecuency ablation) 2.Hypervascular hepatocellular carcinoma proven by imaging test (CT, MRI, US) regardless of the presence or absence of history of TACE 3.Age greater than or equal to 20, <85 4.Written informed consent
Exclusion criteria
Exclusion criteria: 1.Liver dysfunction (Child-Pugh C) 2.Total bilirubin greater than or equal to 3mg/dL 3.eGFR < 30mL/min/1.73m2 4.History of allergy or severe complication of TACE 5.History of severe allergy of platinum-containing drugs including miriplatin or iodine agents 6.Severe thyroid disease 7.Pregnant, unwilling to practice contraception during the study, or lactating female 8.Dementia 9.Inappropriate patients for this study judged by the physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate of each lesion, adverse events, severe adverse events on imaging tests | — |
Contacts
Public ContactTakeyuki Watadani
The University of Tokyo Hospital
Outcome results
None listed